Planas R, Ginès P, Arroyo V, Llach J, Panés J, Vargas V, Salmerón J M, Ginès A, Toledo C, Rimola A
Gastroenterology Unit, Hospital Germans Trias i Pujol of Badalona, Spain.
Gastroenterology. 1990 Dec;99(6):1736-44. doi: 10.1016/0016-5085(90)90481-f.
To investigate whether albumin can be substituted by less expensive plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis, 88 patients (16 with renal failure) submitted to this therapeutic procedure were randomly assigned to receive IV albumin (43 patients) or dextran-70. Both substances were given at a dose of 8 g/L of ascitic fluid removed. Patients were discharged from the hospital with diuretics, and cases developing tense ascites during follow-up were treated according to their initial schedule. Total paracentesis was effective in eliminating the ascites in all but two cases in each group. Neither paracentesis plus IV albumin infusion nor paracentesis plus IV dextran-70 infusion was associated with significant changes in renal and hepatic function or serum electrolytes. The incidence of renal impairment (one case in each group), hyponatremia (three and four cases, respectively), and other complications (hepatic encephalopathy, gastrointestinal hemorrhage, bacterial infections) after paracentesis, and the clinical course of the disease as estimated by the probability of readmission to hospital during follow-up, causes of readmission, probability of survival, and causes of death were similar in the two groups of patients. The effect of paracentesis on effective intravascular volume was indirectly assessed by measuring plasma renin activity and aldosterone concentration before and 2 and 6 days after treatment, the patients being without diuretics. In patients treated with albumin, no significant changes in renin and aldosterone were observed during the entire period of observation. In contrast, both parameters increased significantly on the 6th day of treatment in patients receiving dextran-70. A significant increase in plasma renin activity and aldosterone concentration (30% over baseline values) was observed in 51% of patients treated with dextran-70 and in only 15% of those treated with albumin (x2 = 10.4; P = 0.0012). These results indicate that although dextran-70 is less efficacious than albumin in protecting cirrhotic patients treated with total paracentesis from the decrease in effective intravascular volume, it appears to be capable of preventing the renal and electrolyte complications induced by this therapeutic procedure.
为了研究在接受完全腹腔穿刺术治疗的肝硬化张力性腹水患者中,白蛋白是否可用成本较低的血浆扩容剂替代,88例接受该治疗程序的患者(16例伴有肾衰竭)被随机分配接受静脉输注白蛋白(43例患者)或右旋糖酐70。两种物质均按每升抽出腹水给予8 g的剂量给药。患者出院时带有利尿剂,随访期间发生张力性腹水的病例按初始方案治疗。完全腹腔穿刺术在每组除两例外的所有病例中均有效消除了腹水。腹腔穿刺术加静脉输注白蛋白或腹腔穿刺术加静脉输注右旋糖酐70均未导致肾功能、肝功能或血清电解质的显著变化。腹腔穿刺术后肾功能损害(每组1例)、低钠血症(分别为3例和4例)及其他并发症(肝性脑病、胃肠道出血、细菌感染)的发生率,以及根据随访期间再次入院概率、再次入院原因、生存概率和死亡原因评估的疾病临床过程,在两组患者中相似。通过在治疗前以及治疗后第2天和第6天测量血浆肾素活性和醛固酮浓度来间接评估腹腔穿刺术对有效血管内容量的影响,患者未使用利尿剂。在接受白蛋白治疗的患者中,在整个观察期内肾素和醛固酮未观察到显著变化。相比之下,接受右旋糖酐70治疗的患者在治疗第6天时这两个参数均显著升高。在接受右旋糖酐70治疗的患者中,51%观察到血浆肾素活性和醛固酮浓度显著升高(超过基线值30%),而接受白蛋白治疗的患者中仅15%出现这种情况(χ2 = 10.4;P = 0.0012)。这些结果表明,虽然在保护接受完全腹腔穿刺术治疗的肝硬化患者避免有效血管内容量减少方面,右旋糖酐70不如白蛋白有效,但它似乎能够预防该治疗程序引起的肾和电解质并发症。